ArticleBMC cancer2018

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.

Shuling Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.